Hepion Pharmaceuticals, Inc. (HEPA) Key Metrics
HEPA valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $14.8M
- Enterprise value
- $5.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 41.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.75
HEPA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsHEPA returns How much profit the business earns on the capital it uses.
HEPA financial health Debt, liquidity and how easily interest is covered.
HEPA returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
HEPA debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
HEPA cash returned to shareholders
HEPA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $0.06 | $23.50 | $162.00 | $300.30 | $1,140.00 | $2,190.00 | $5,360.00 | $19,740.00 | $201,600.00 | $672,000.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | −171.3% | −59.1% | −49.0% | −72.5% | −80.0% | −332.8% | −598.4% | −714.7% |
| Return on invested capital (ROIC) | −431.7% | — | — | — | — | — | −398.1% | — | — | — |
| Return on assets (ROA) | −353.5% | −133.9% | −124.9% | −51.5% | −43.0% | −58.8% | −48.9% | −97.2% | −123.3% | −183.9% |
| Return on tangible assets | −269.6% | −817.5% | −270.4% | −74.0% | −33.2% | −46.7% | −45.3% | −302.1% | −242.6% | −211.3% |
| Financial health | ||||||||||
| Total debt | $54,066 | $2.9M | $209,020 | $53,614 | $316,992 | $752,166 | $807,447 | $1.4M | — | $10,410 |
| Cash & short-term investments | $1.8M | $406,408 | $14.8M | $51.2M | $91.3M | $40.7M | $13.9M | $2.8M | $6.0M | $7.4M |
| Net debt | −$1.8M | $2.5M | −$14.6M | −$51.1M | −$91.0M | −$40.0M | −$13.1M | −$1.4M | −$6.0M | −$7.4M |
| Debt / equity | 0.02 | — | 0.03 | 0.00 | 0.00 | 0.02 | 0.05 | 0.73 | — | 0.01 |
| Debt / assets | 0.02 | 1.80 | 0.01 | 0.00 | 0.00 | 0.02 | 0.04 | 0.18 | — | 0.00 |
| Current ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 | 8.94 | 1.04 | 2.33 | 1.55 |
| Quick ratio | 10.25 | 0.51 | 3.31 | 7.16 | 11.88 | 9.15 | 8.94 | 1.04 | 2.33 | 1.55 |
| Interest coverage | -170.6 | -15.5 | — | — | — | -645.1 | -14.0 | -43.0 | -5.0 | -5.5 |
| Working capital | $2.8M | −$1.5M | $12.2M | $48.6M | $89.2M | $38.0M | $12.8M | $118,171 | $3.5M | $2.8M |
| Invested capital | $893,551 | $630,254 | −$7.3M | −$1.3M | $2.0M | $545,719 | $2.5M | $582,622 | −$2.3M | −$6.1M |
| Tangible asset value | $2.7M | −$1.9M | $7.3M | $46.7M | $87.9M | $35.5M | $10.6M | −$3.1M | −$1.4M | −$3.7M |
| Net current asset value | $2.7M | −$1.9M | $6.7M | $46.1M | $86.9M | $34.5M | $9.4M | −$3.2M | −$1.5M | −$3.9M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $1,000 | $5,000 | $11,000 | $10,000 | $147,000 | $4.7M | — | — |
| Share buybacks (net) | — | — | $0 | $21.0M | $0 | $0 | $0 | $0 | $0 | $0 |
| Capex / depreciation | 0.00 | 0.47 | 0.21 | 0.21 | 1.52 | 2.55 | 1.93 | 2.74 | 0.00 | 0.31 |
| Efficiency | ||||||||||
| Days payables outstanding | — | 15,243.1 | 13,632.9 | 12,043.4 | 13,078.5 | 22,281.7 | 8,463.8 | 22,394.2 | 48,325.5 | 48,612.7 |
| Payables turnover | — | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 | 0.04 | 0.02 | 0.01 | 0.01 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $194,006 | $1.3M | $2.5M | $2.6M | $3.1M | $2.1M | $619,992 | $1.2M | $2.9M | $2.9M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 5.3% | 4.9% | 10.4% | 24.6% | 61.8% | 45.0% | 38.6% |
Computed from HEPA's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
HEPA valuation and financial ratios
Hepion Pharmaceuticals earned a return on invested capital of −431.7% in fiscal 2025. It ended the year with $0.1 million of debt and $1.8 million in cash and short-term investments, a net cash position of $1.8 million.
See the HEPA income statement, the HEPA chart for price history, or the HEPA stock overview for the latest quote and news.
HEPA key metrics FAQ
What is Hepion Pharmaceuticals's ROIC?
Hepion Pharmaceuticals's return on invested capital was −431.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Hepion Pharmaceuticals have?
Hepion Pharmaceuticals had total debt of $0.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Hepion Pharmaceuticals's current ratio?
Hepion Pharmaceuticals's current ratio was 10.25 at the end of fiscal 2025: current assets were 10.25 times current liabilities.